GlassScriptPhysician profile
Deepica G Reddy
NPI 1841262318
$4,958.99
in general payments reported to CMS, 2019-2025
32 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $390 · 2020: $558 · 2021: $2,317 · 2022: $703 · 2023: $747 · 2024: $243.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $990.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $990.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $1,333.62 | 2021 | |
| Novo Nordisk INC | $663.42 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $355.10 | 2019-2023 | Breztri |
| Abbvie INC. | $338.35 | 2020-2023 | |
| Pfizer INC. | $307.80 | 2019-2023 | |
| Amgen INC. | $255.35 | 2019-2023 | Repatha, Otezla |
| Lilly USA, LLC | $223.85 | 2019-2023 | Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $207.33 | 2019-2023 | Jardiance |
| Edwards Lifesciences Corporation | $206.79 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Amarin Pharma, INC. | $101.13 | 2020-2021 | |
| Glaxosmithkline, LLC. | $100.76 | 2022-2023 | Shingrix, Arexvy |
| Abbott Laboratories | $74.24 | 2023-2024 | Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $68.08 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $64.83 | 2019-2023 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $63.58 | 2020-2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $61.62 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $60.11 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $57.31 | 2021-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $56.64 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $48.16 | 2022-2023 | |
| Daiichi Sankyo INC. | $47.38 | 2019-2022 | |
| Arbor Pharmaceuticals, INC. | $44.36 | 2019-2020 | |
| Eisai INC. | $39.72 | 2020-2021 | |
| Horizon Therapeutics Plc | $33.62 | 2020 | |
| Sanofi Pasteur INC. | $23.90 | 2023 | |
| Allergan, INC. | $23.74 | 2020 | |
| Dynavax Technologies Corporation | $20.24 | 2023 | Heplisav-B |
| Exact Sciences Corporation | $19.25 | 2023 | Cologuard Collection Kit |
| Idorsia Pharmaceuticals US INC | $17.70 | 2022 | |
| Xeris Pharmaceuticals, INC. | $14.76 | 2022 | |
| Paratek Pharmaceuticals, INC. | $13.67 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $12.58 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deepica Reddy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.